SK Bioscience IPO subscription is in full swing ...Biopharma stock fever
SK Bioscience IPO subscription is in full swing ...Biopharma stock fever
  • 이지선 기자
  • 승인 2021.03.02 08:22
  • 최종수정 2021.03.02 07:37
  • 댓글 0
이 기사를 공유합니다

This article is translated by AI company Flitto and Infostock Daily using neural machine translation technology. 


sk바이오사이언스 CI
SK Bioscience CI

[Infostock Daily=Reporter Lee Ji-sun] In the first half of this year, SK Bioscience, a vaccine company considered one of the largest Initial Public Offering (IPO) companies, started offering shares this month.

According to the financial investment industry on the 1st, SK Bioscience will begin the process of subscribing to public offering stocks, starting with institutional investor demand forecasts to finalize public offering prices from the 3rd to the 4th.

Based on the public offering price, the company will receive applications for general public offering shares from the 9th to the 10th. The stock will be listed on the securities market on the 18th.

SK Bioscience is a vaccine specialist that was injected by SK Chemicals in July 2018. SK Bioscience is attracting investors'attention in that it is a vaccine development and consignment producer in the new coronavirus (COVID-19) phase.

As a result, SK Bioscience is expected to bring a craze for subscription of public shares as much as SK BioPharm.

The total number of shares of SK Bioscience is 22.95 million shares, with the desired public offering price of 49,000 to 65,000 won and the initial public offering amounting to at least 1.1245 trillion won.

Sales and net profit in 2019 are 183.9 billion won and 14.6 billion won, respectively, far exceeding SK BioPharm, which recorded net loss of 91 billion won with sales of 123.8 billion won in the same year. 

Reporter Lee Ji-sun

삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.